GLP-1
A Phase III trial compared Sanofi’s Soliqua/Suliqua to other GLP-1 receptor agonists (GLP-1 RA), with Soliqua showing a superior decrease of average blood sugar level (HbA1c) after 26 weeks.
Adocia announces the initiation of a Phase 1b study of ADO09, a ready-to-use, fixed ratio co-formulation of pramlintide, the only FDA-approved analog of amylin, and A21G human insulin analog, a rapid-acting insulin that is known to be the main circulating metabolite of insulin glargine.
Breakthrough in industrial large-scale manufacturing of well-defined biomedical fiber-based scaffolds for a wide variety of medical applications
The FDA extended the indication for Gattex to pediatric patients one year of age and older with short bowel syndrome.
Under the terms of the deal, Pfizer will pay $340 million up front with another $470 million in payments contingent on milestones for the development and commercialization of TA-46 for the treatment of achondroplasia.
Novo Nordisk announced positive results from its ELLIPSE Phase III clinical trial of Victoza (liraglutide) in treating type 2 diabetes in children aged 10 to 17. The company presented the results at the Pediatric Endocrine Society (PES)/Pediatric Academic Societies (PAS) Annual Meeting held in Baltimore, MD, and simultaneously published in the New England Journal of Medicine.
Galapagos NV presents financial results and highlights the key events for the first quarter of 2019.
MorphoSys AG, Galapagos NV and Novartis Pharma AG announced the initiation of GECKO, a phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.
Galapagos NV, MorphoSys AG and Novartis Pharma AG announced the initiation of GECKO, a Phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.
Here’s a look at six San Francisco Bay Area life science companies that have hit a variety of “best of” lists recently, in no particular order.
PRESS RELEASES